Low CPNE3 expression is associated with risk of acute myocardial infarction: A feasible genetic marker of acute myocardial infarction in patients with stable coronary artery disease by Tan, Buchuan et al.
Address for correspondence: Dr. Fanbo Meng, Cardiology Department of the China-Japan Union Hospital of Jilin University, 
NO.126, Xiantai Street, Changchun City, China, post number: 130033, tel: +86-431-84995228, e-mail: mengfb@jlu.edu.cn
Received: 25.09.2017 Accepted: 15.12.2017
BASIC SCIENCE AND EXPERIMENTAL CARDIOLOGY
Cardiology Journal 
2019, Vol. 26, No. 2, 186–193
DOI: 10.5603/CJ.a2017.0155 
Copyright © 2019 Via Medica
ISSN 1897–5593
186 www.cardiologyjournal.org
ORIGINAL ARTICLE
Low CPNE3 expression is associated with risk 
of acute myocardial infarction: A feasible genetic 
marker of acute myocardial infarction in patients 
with stable coronary artery disease
Buchuan Tan1, Long Liu1, Yushuang Yang1, Qian Liu1, Liping Yang2, Fanbo Meng1
1Cardiology Department of the China-Japan Union Hospital of Jilin University, Changchun, China 
2Peking University Shenzhen Hospital, Shenzhen, China 
Abstract 
Background: Gene COPINE III may be related to a phosphoprotein with intrinsic kinase activity and 
belongs to an unconventional kinase family. The CPNE3 gene may be used as a biomarker for assess-
ment of occurrence and prognosis of various tumors.
Methods: Peripheral blood was collected from 87 stable coronary artery disease (CAD) patients and 
91 acute myocardial infarction (AMI) patients. Real-time quantitative polymerase chain reaction test and 
the western blot method were adopted to measure expression quantity of CPNE3 gene at the mRNA level 
and the protein level.
Results: The expression of the CPNE3 gene in peripheral blood of AMI patients was significantly lower 
than those in peripheral blood of stable CAD patients. Low expression of CPNE3 gene was found to be 
unrelated to level of fasting blood glucose and serum blood lipid of patients, quantity of cardiac troponin 
and time of onset but was found to be correlated to the Gensini score for coronary artery. When the ex-
pression of CPNE3 gene at the mRNA level in peripheral blood was used as the criterion for diagnosing 
AMI, its sensitivity, specificity, positive predictive value and negative predictive value were 69%, 64.8%, 
68.6% and 65.2%, respectively.
Conclusions: Compared to stable CAD patients, AMI patients have a lower expression of CPNE3 gene 
in their peripheral blood. Patients who have low CPNE3 expression in peripheral blood are more likely 
to suffer from AMI than those with stable CAD. Low expression of CPNE3 gene serves as an potential 
independent risk factor of AMI. (Cardiol J 2019; 26, 2: 186–193)
Key words: CPNE3 gene, acute myocardial infarction, stable coronary artery disease, 
independent risk, peripheral blood, genetic marker
Introduction
In the United States, 40% of all cases of death 
every year are related to coronary artery disease 
(CAD) and it is estimated that such disease will 
be a major cause of death around the world in the 
next decades [1]. In particular, there is a potential 
and fatal risk of acute myocardial infarction (AMI) 
in the progression of CAD [2, 3]. In patients with 
CAD, conventional risk factors were present at 
a much higher prevalence than commonly be-
lieved, with 15% to 20% of patients lacking any of 
the conventional risk factors for the disease [4]. 
Just like other chronic diseases, CAD is a complex 
polygenic disease, based on the incidence rate of 
AMI which increases with age, which is jointly 
caused by genetic factors and environmental fac-
tors [5]. 
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According to various literature, gene expres-
sion level in peripheral blood can reflect changes of 
various complex diseases including cardiovascular 
disease and serves as an extremely significant bio-
marker for detection and verification of diseases [6, 7]. 
For example, serving as a potential inflammation 
marker, an increase in expression of a-defensin in 
peripheral blood may serve to predict the risk of 
CAD occurrence among hyperlipidemia patients [8]. 
Gene COPINE III may be related to a phospho-
protein with intrinsic kinase activity and belongs 
to an unconventional kinase family [9]. It may have 
an influence on membrane protein, lipid and other 
activities [10]. CPNE3 gene can be used to predict 
metastatic potential of small cell lung cancer and 
serves as an index for prognosis of patients or 
a therapeutic target [11]. Moreover, the CPNE3 
gene also plays a role with high correlation in 
carcinogenesis of prostate cancer [12]. It has also 
been proved that CPNE3 gene is correlated to 
schizophrenia [13].
The result of a previous analysis on profile of 
differential gene expression (2 pools, 3 subjects in 
each pool) in peripheral blood for AMI conducted 
by this research team indicates that AMI patients 
have a lower expression in their peripheral blood 
than stable CAD patients, for which the time of 
expression is 0.484 time. Therefore, by using the 
method of expanding the sample size of clinical 
data, this research aims to verify the relationship 
of CPNE3 gene AMI.
Methods
Subjects
Among patients admitted into Department of 
Cardiovascular Medicine, China-Japan Union Hospi-
tal of Jilin University from April 2016 to September 
2016 and subject to coronary angiography, 91 pa-
tients definitively diagnosed with AMI according to 
the global uniform definition of myocardial infarction 
issued in 2012 [14] were selected to form the AMI 
group and 87 patients diagnosed with stable CAD 
[15] based on 2013 European Society of Cardiology 
guidelines were selected to form the control group 
(1. Narrowing of ≥ 50% in the left main coronary 
artery and ≥ 70% in one or several of the major 
coronary arteries. 2. The duration of discomfort is 
brief — no more than 10 min in the majority of cases 
and more commonly even several minutes or less). 
Statement of ethical approval
The Ethics Committee, China-Japan Union 
Hospital of Jilin University approved this research. 
Collection of samples and information about all 
subjects was approved by the subjects, from whom 
informed consent forms were signed.
Peripheral blood collection, total RNA  
extraction and cDNA synthesis
The collection of 4 mL of peripheral venous 
blood of each subject and conducting total RNA 
extraction from the collected peripheral blood by 
using total RNA extraction reagent kit was carried 
out (RNAsimple Total RNA Kit, Tiangen Biotech 
(Beijing) Co. Ltd. Beijing) according to instructions 
on the reagent kit. Reverse transcription of 1 µg 
of the qualified total RNA was conducted by using 
reverse transcription reagent kit (TOYOBO Rever 
Tra Ace qPRC RT kit, Shanghai) and the obtained 
cDNA sample was stored under conditions with 
a temperature of -20°C for real-time (RT) quan-
titative polymerase chain reaction (PCR) in the 
next step.
Real-time quantitative PCR test
Polymerase chain reaction amplification was 
conducted with SYBR real-time quantitative PCR 
reagent kit (SYBR Premix Ex Taq TM, TaKaRa, 
Dalian). The 20 µL-reaction system was adopted, 
for which each reaction included: 10 µL of SYBR 
Premix Ex Taq TM, 0.5 µL of forward primer and 
0.5 µL of reverse primer (concentration should be 
10 µmol/L), 8 µL of nuclease-free double distilled 
water and 1 µL of cDNA template. Amplification 
was realized by using Mx3005P RT quantitative 
PCR system (Strata Gene). Relative expression 
quantity 2–DCt (DCt = Target Gene Ct Value — 
Reference Gene Ct Value) was used to express 
the obtained cycle thresholds (Ct) of each sample 
and a comparison was conducted [16]. Design of 
PCR primer was conducted according to CPNE3 
gene sequence provided by NCBI Database and 
synthesis was completed by Shanghai-based 
Sangon Biotech. Primer sequence is indicated 
in Table 1.
Table 1. Sequence of RT-PCR primers.
Genes Genes primer sequence (5’–3’)
CPNE3 Fa GTCAGACCCTTTATGTGTGTTGT
Rb TGGAAAATTGGGGATTCAAGCAA
GAPDH Fa ACGGATTTGGTCGTATTGGGCG
Rb CTCCTGGAAGATGGTGATGG
Fa — sequence from sense strands; Rb — sequence from anti-sense 
strands
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Statistical analysis
All data were statistically analyzed with 
SPSS24.0 software. When the measured data 
conformed to normal distribution, statistical de-
scription was conducted by using X ± S and inter-
group difference comparison was realized through 
using independent T test analysis. When measure-
ment data did not conform to normal distribution, 
median and inter-quartile range was adopted to 
conduct statistical description and inter-group 
difference comparison was realized with rank-sum 
test. Statistical description of enumeration data 
was realized through the use of frequency num-
ber and c2 test to analyze inter-group differences. 
Binary logistic regression analysis was conducted 
to analyze relevant risk factors of AMI. As for the 
correlation between relative expression quantity 
of CPNE3 gene, cardiac troponin I and Gensini 
score, double-variable correlation analysis was 
conducted to analyze any correlation. Statistical 
result characterized by p < 0.05, bilaterally, was 
deemed as having statistical significance.
Results
Clinical data analysis
It is indicated by the results of clinical data 
analysis on the subjects that: There is no signifi-
cant statistical difference between the two groups 
in the following aspects: Age, sex, body mass 
index, history of hypertension, family history of 
coronary heart disease, systolic pressure, trigly-
ceride (TG), total cholesterol (TC), low density 
lipoprotein cholesterol (LDL-C) and high density 
lipoprotein cholesterol (HDL-C). Those patients 
in the AMI group are older than patients in the 
stable CAD group and such difference is statisti-
cally significant (t = 2.063, p = 0.041). It was also 
found that left ventricular ejection fraction (EF) 
was significantly different between the two groups 
(Z = –3.530, p = 0.000; see Table 2 for details). 
Comparative analysis on relative  
expression quantity of CPNE3 gene at  
the mRNA level between the AMI group 
and the stable CAD group
DCt value of each sample obtained through 
RT-PCR was the mean value obtained through 
three repeated measurements on each sample. 
The results indicate that 2–DCt of the AMI group 
is 0.020 (0.016–0.032) and 2DDCt of the stable CAD 
group was 0.029 (0.021–0.067), for which there 
is a significant statistical difference (Z = –4.231, 
p = 0.000) between these two groups. The relative 
expression quantity of CPNE3 gene at the mRNA 
level in peripheral blood of patients in the AMI 
Table 2. Comparison of clinical data between the acute myocardial infarction (AMI) group and the stable 
coronary artery disease (CAD) group.
Categories of data The AMI group (n = 91) The stable CAD group (n = 87) t/c²/z P
Age [years] 64.55 ± 11.464 61.32 ± 8.452 2.063 0.041
Sex: 0.186 0.666
Male 60 (65.9) 69 (69.0)
Female 31 (34.1) 27 (31.0)
BMI [kg/m²] 24.802 (22.477–27.357) 25.799 ± 3.209 –1.711 0.087
Hypertension 44 (48.4) 45 (51.7) 0.202 0.653
Family medical history 7 (7.7) 4 (4.6) 0.718 0.397
Systolic pressure [mmHg] 133.73 ± 23.488 136.04 ± 20.524 –0.350 0.727
Diastolic pressure [mmHg] 81 (75.75–91) 80.84 ± 12.61 –1.136 0.256
Smoking history 41 (45.1) 40 (46.0) 0.015 0.902
Diabetes 20 (22.0) 28 (32.2) 2.352 0.125
Fasting blood-glucose [mmol/L] 6.03 (5.085–8.235) 5.81 (5.240–8.170) –0.360 0.719
Total cholesterol [mmol/L] 4.553 ± 1.358 4.334 ± 1.010 1.194 0.234
Triglyceride [mmol/L] 1.57 (1.160-2.303) 1.74 (1.140–2.500) –0.500 0.617
LDL-C [mmol/L) 3.091 ± 1.101 2.855 ± 0.844 1.569 0.118
HDL-C [mmol/L] 0.94 (0.805–1.133) 0.88 (0.770–1.070) –0.896 0.370
Ejection fraction [%] 63 (42–65) 65 (63–67.5) –3.530 0.000
BMI — body mass index; HDL-C — high density lipoprotein cholesterol; LDL-C — low density lipoprotein cholesterol
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group was significantly lower than that of patients 
in the stable CAD group, for which the relative 
expression quantity of CPNE3 gene of the AMI 
group is 0.69 times that of the stable CAD group 
(see Figure 1 for details).
Analysis on the result of expression  
of CPNE3 gene at the protein level  
in peripheral blood
Western blot was conducted on peripheral blood 
of patients with b-actin as the reference. The results 
indicated that the relative expression of CPNE3 was 
0.925 ± 0.118 in the AMI group and 2.599 ± 0.261 
in the stable CAD group. Compared to stable CAD 
patients, AMI patients have a low expression of 
CPNE3 at the protein level in their peripheral blood 
and the expression of CPNE3 of the AMI group at 
the protein level is 0.356 times that of the stable 
CAD group (see Figure 2 for details).
Analysis on correlation between expression 
quantity of CPNE3 gene and age, serum 
blood lipid and blood glucose, ejection  
fraction of patients
Based on stratification standard for blood lipid 
level [17], all subjects included were divided into 
groups: with normal TC (< 5.18 mmol/L), with 
increased TC (≥ 5.18 mmol/L),  with normal TG 
(< 1.76 mmol/L) with increased TG (≥ 1.76 mmol/L), 
with normal LDL-C (< 3.37 mmol/L) with increased 
LDL-C (≥ 3.37 mmol/L),with normal HDL-C 
(≥ 0.907 mmol/L) and the group with decreased 
HDL-C (< 0.907 mmol/L). Based on the standard 
level of fasting blood glucose [18], all subjects were 
divided into groups with normal level of fasting 
blood glucose (≤ 6.0) and a group with an increased 
level of fasting blood glucose (> 6.0). Based on 
standard age groups of Chinese people, all subjects 
were divided into groups at an advanced age (> 65) 
and at a younger age (≤ 65). All the subjects were 
divided into groups with normal EF (≥ 50%) and with 
low EF (< 50%). The result indicates that there is 
a difference (p = 0.008) in the expression quantity 
of the CPNE3 gene at the mRNA level between the 
group at an advanced age and the group at a younger 
age (see Table 3 for detail of the results).
Analysis on correlation between expression 
quantity of CPNE3 gene at mRNA level 
and age of patient and AMI using logistic 
regression analysis
Based on the cut-off value of relative expres-
sion quantity of CPNE3 gene, all the subjects were 
divided into a group with high expression quantity 
(2–DCt > 0.013) and a group with low expression 
quantity (2–DCt ≤ 0.013). The result indicates that: 
Low expression of CPNE3 is a factor closely related 
with AMI, the OR value increased 3.845 fold re-
spectively. Relatively advanced age is also a factor 
Figure 1. Comparative analysis on relative expression 
quantity of CPNE3 gene at the mRNA level between the 
acute myocardial infarction (AMI) group and the stable 
coronary artery disease (CAD) group.
Figure 2. Comparison of expression level of CPNE3 
gene at the protein level. For the acute myocardial in-
farction (AMI) group, sample numbers are 1, 2 and 3; 
For the stable coronary artery disease (CAD) group, 
sample numbers are 4, 5 and 6.
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closely related with AMI, the OR value was 2.605 
fold, respectively. Correlation of estimate between 
low expression and relatively advanced age is 
(rs = –0.451, p = 0.000; see Table 4 for details). 
ROC curve and cut-off value of relative  
expression quantity of CPNE3 gene  
in diagnosis of AMI
Based on the relative expression quantity of 
CPNE3 gene, the 2-DCt value, acquired through PCR, 
receiver operating characteristic (ROC) curve 
was created, as indicated in Figure 3. It is known 
from Figure 3 that the area under curve (AUC) 
is 0.684 ± 0.040 and the cut-off value of relative 
expression quantity of CPNE3 gene determined 
is based on the maximum value of Youden index 
is 0.024, for which sensitivity and specificity for 
diagnosis of AMI are 0.690 and 0.648, respectively. 
Positive predictive value and negative predictive 
value are 68.6% and 65.2%, respectively (see Fig-
ure 3 for details).
Figure 3. Receiver operating characteristic (ROC) curve 
CPNE3 gene in diagnosis of acute myocardial infarction.
Diagonal segments are produced by ties.
Table 3. Analysis on correlation between expression quantity of CPNE3 gene at the MRNA and age of 
patient, blood glucose, levels of serum TC, HDL-C and LDL-C, ejection fraction of patients.
Group Number of patients Relative expression quantity of CPNE3 Z P
Normal blood glucose 71 0.029 (0.019–0.064) –0.739 0.460
Increased blood glucose 72 0.024 (0.018–0.045)
Normal total cholesterol 133 0.025 (0.018–0.048) –0.554 0.580
Increased total cholesterol 38 0.028 (0.018–0.076)
Normal triglyceride 101 0.028 (0.019–0.064) –0.768 0.442
Increased triglyceride 70 0.025 (0.0017–0.043)
Normal LDL-C 121 0.025 (0.018–0.046) –0.503 0.615
Increased LDL-C 50 0.030 (0.017–0.084)
Normal HDL-C 94 0.025 (0.018–0.045) –1.318 0.188
Decreased HDL-C 77 0.026 (0.018–0.059)
Younger age 116 0.030 (0.019–0.070) –2.635 0.008
Advanced age 62 0.022 (0.017–0.030)
Normal ejection fraction 108 0.026 (0.018–0.042) –1.434 0.152
Low ejection fraction 23 0.046 (0.021–0.070)
HDL-C — high density lipoprotein cholesterol; LDL-C — low density lipoprotein cholesterol; TC — total cholesterol
Table 4. Result of logistic regression analysis on independent risk factors of acute myocardial infarction.
Regression  
coefficient
Standard 
error
Wald P Odds  
ratio
95% confidence  
interval
Low expression of CPNE3 gene 1.347 0.326 17.022 0.000 3.845 2.028–7.292
Relatively advanced age 0.957 0348 7.583 0.006 2.605 1.318–5.149
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Double-variable correlation analysis between 
relative expression quantity of CPNE3 
gene and degree of severity of coronary 
artery lesion, cardiac troponin I, interval 
from timespan of onset of AMI of patients 
to blood collection
The result of Gensini score of all subjects was 
25 (9.5–52). The expression quantity of CPNE3 
at the mRNA level was negatively correlated to 
Gensini score (rs = –0.200, p = 0.018). 
The test result of cardiac troponin for the AMI 
group is 0.790 (0.138–8.760) ng/mL. Concentration 
of serum troponin I (TnI) can reflect the scope of 
AMI. The expression quantity of CPNE3 gene in 
peripheral blood is unrelated to serum TnI concen-
tration (rs = –0.144, p = 0.364). 
The incipient long-time (≥ 20 min) rest pain of 
patients suffering from AMI in the last week was 
considered as the time of onset and the interval 
from onset of AMI of patients in the AMI group 
to the time when blood was collected should be 
the time interval of occurrence, for which the 
result was 24 (11–72) h. There was no correlation 
between the expression quantity of CPNE3 gene 
and timespan (rs = –0.098, p = 0.533).
Discussion
The role played by the Copine family in cells 
still remains unknown although some studies have 
indicated that it might have an influence on mem-
brane protein, lipid and other activities [10]. It has 
been reported that the interaction between CPNE3 
and ErbB2 could promote tumor metastasis, which 
played a role in non-small cell lung cancer, breast 
cancer, prostate cancer and ovarian tumor [11, 
12, 19]. However, there is no study on the role 
played by CPNE3 in occurrence and progression 
of cardiovascular disease. This study focused on 
investigating the expression quantity of CPNE3 
gene in peripheral blood of AMI patients and found 
that it was significantly lower than that of stable 
CAD patients at both the mRNA and protein levels. 
CPNE3 mRNA expression with clinical vari-
ables were correlated, including blood glucose, 
serum TC, TG, LDL-C or HDL-C, age, and EF. 
As a result, a significantly different expression 
of CPNE3 was found between patients with AMI 
and patients with stable CAD. Further analysis 
indicated that abnormal expression quantity of 
CPNE3 gene was irrelevant to EF values. Ac-
cording to a previous study, patients with AMI had 
a preponderance to develop REF/HFREF due to 
irreversible myocardial damage. It was particularly 
true in large transmural/ST-segment elevation 
myocardial infarction infarcts [20]. Thus, the sig-
nificant difference of CPNE3 gene expressions in 
the present study is not due to reduced EF since 
AMI leads to reduced EF. 
Prevalence and fatality rate of AMI was re-
ported to increase with age [21]. Currently, age 
remained a strong independent predictor of both in 
hospital and 1-year post-discharge mortality rates 
in patients with AMI [22]. Binary logistic analysis 
showed that low expression of CPNE3 gene was an 
independent risk factor for AMI (OR 3.845; p < 0.05) 
and age also was an independent risk factor for 
AMI (OR 2.605; p < 0.05). Regardless of age and 
other factors, low expression of CPNE3 gene could 
increase the risk of AMI in stable CAD patients by 
3.845 times. While advanced age of patients alone 
could increase the risk of AMI by 2.605 times. 
Thus, it was speculated that older patients who 
have low CPNE3 expression would be more likely 
to suffer from AMI. 
CPNE3 was shown to participate in immune-
regulation and neutrophil degranulation, including 
metabolism of lipids such as fatty acid, triglyceride, 
lipoprotein and ketone bodies (from REACTOME). 
Conventional risk factors of CAD [23–25], hyper-
tension [25], hypercholesterolemia [26], diabetes, 
[27] obesity, [28] smoking, [25, 29] and family 
history [30] were believed to have an adverse 
influence on prognosis in those with established 
disease, presumably through their effect on the 
progression of atherosclerotic disease processes. 
However, the present study demonstrated that 
low expression of CPNE3 was unrelated to blood 
glucose, serum TC, TG, LDL-C, and HDL-C. It 
was speculated that the mechanism of CPNE3’s 
role in promoting AMI may be not through lipid 
metabolism or blood glucose.
Although the mechanism of CPNE3’s role in 
promoting the occurrence of AMI is still unknown. 
Results herein indicate that the relative expression 
quantity of CPNE3 gene is correlated to Gensini 
score, which defines the severity of coronary 
artery lesion. Gensini score has been reported 
to be mainly correlated to the degree of coronary 
stenosis and scope of blood supply [31]. Therefore, 
lower expression of CPNE3 may lead to a higher 
severity of coronary artery lesion.
Quantity of cardiac troponin predicts the extent 
of myocardial infarction. This study showed that 
expression quantity of CPNE3 gene was unrelated to 
a concentration of TnI. Furthermore, the present 
study indicated that there was also no correlation 
between the expression quantity of CPNE3 gene 
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in peripheral blood and timespan of AMI. If a low 
expression of CPNE3 had occurred with AMI, 
expression quantity of CPNE3 gene should be cor-
related to concentration of TnI and the timespan and 
vice versa. In our case, low expression of CPNE3 
gene didn not occur with AMI and thus might serve 
as one of the causes of AMI which was supported 
by the ROC curve of CPNE3 mRNA expression in 
diagnosing AMI.
Therefore, it was speculated that low expres-
sion of CPNE3 gene may increase the risk of AMI 
by promoting formation of coronary artery lesion. 
Although it is not conclusive if low expression 
of CPNE3 causes AMI, it is speculated that low 
CPNE3 expression is a cause of AMI. To confirm 
this, a prospective randomized study is indispen-
sable. More experiments of CPNE3 functions and 
investigation of its mechanism of molecular biology 
are also required.
Conclusions
Acute myocardial infarction patients have the 
lower expression of CPNE3 gene in their periph-
eral blood in comparison to stable CAD patients. 
There is an association between low expression 
of CPNE3 and AMI. Patients who have a lower 
CPNE3 expression in peripheral blood are more 
likely to suffer from AMI than other patients with 
stable CAD. Low expression of CPNE3 gene serves 
as a potential independent risk factor of AMI.
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